Our focus is on research, acquisition, development, licensing, and marketing of pharmaceutical products but we benefit from being part of a global family of specialists. Each division can utilise the experience of the Kowa Company, Ltd. network to ensure that processes are streamlined and constantly evolving to meet the needs of all our customers.
Pitavastatin demonstrates no significant drug-to-drug interaction when administered with CYP3A4 inhibitors
Pitavastatin demonstrates no significant drug-to-drug interaction
Pitavastatin demonstrates no significant drug-to-drug interaction when administered with CYP3A4 inhibitors. Data shows potential tolerability advantage for pitavastatin compared with other statins.
BARCELONA, 2nd September 2009 - New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on the pharmacokinetics of pitavastatin, in healthy volunteers.